Sort
89,613 grants matching “depression”
MACS/WIHS -CCS
$2,599,372Margaret A Fischl · University Of Miami School Of Medicine · U01 · FY2021 · HL
Mitochondrial transport and energy metabolism in synaptic transmission and neuronal degeneration and regeneration
$2,598,611Zu-Hang Sheng · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Scientific and Statistical Computing Core
$2,597,359Paul Taylor · National Institute Of Mental Health · ZIC · FY2023 · MH
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
$2,596,763Martha J Morrell · Neuropace, Inc. · UH3 · FY2022 · NS
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
$2,596,126Jose Szapocznik · University Of Miami School Of Medicine · UG1 · FY2016 · DA
Emergency Department Screen for Teens at Risk for Suicide (ED-STARS)
$2,595,239Cheryl A King · University Of Michigan At Ann Arbor · U01 · FY2016 · MH
Novel Therapeutics for Opioid Use Disorder in the Acute Overdose and Maintenance Settings
$2,594,546Donald R Gehlert · Epiodyne, Inc. · UH3 · FY2022 · DA
Section on Light and Circadian Rhythms
$2,593,237Samer Hattar · National Institute Of Mental Health · ZIA · FY2022 · MH
UTRGV Diversity Center for Genome Research
$2,591,438Sarah A. Williams-Blangero · University Of Texas Rio Grande Valley · U54 · FY2023 · HG
MACS/WIHS -CCS
$2,590,415Maria Luisa Alcaide · University Of Miami School Of Medicine · U01 · FY2025 · HL
RISK FACTORS IN CHILDHOOD ONSET DEPRESSION
$2,590,341University Of Pittsburgh At Pittsburgh · P01 · FY2001 · MH
FKBP51 antagonism to prevent chronic pain: optimizing efficacy & evaluating safety and mechanisms
$2,589,652Sarah Linnstaedt · Univ Of North Carolina Chapel Hill · R01 · FY2020 · NS
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?
$2,584,873Kyle Matthew Kampman · University Of Pennsylvania · UH3 · FY2025 · DA
Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain
$2,579,875Malcolm A Meyn · Amalgent Therapeutics, Inc. · R44 · FY2023 · DA
Data and Analysis Core
$2,578,891Matthew Douglas Johnson · University Of Minnesota · U54 · FY2024 · AT
Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)
$2,576,269Kimford J Meador · Stanford University · U01 · FY2021 · NS
Risk Factors for Onset and Persistence of TMD
$2,575,925William Maixner · Univ Of North Carolina Chapel Hill · U01 · FY2007 · DE
Depression, Biobehavioral Mechanisms, & CHD/Mortality Outcomes
$2,575,728Karina W. Davidson · Columbia University Health Sciences · P01 · FY2012 · HL
Alcohol Pharmacokinetics and Pharmacodynamics in Humans
$2,574,912Vijay Arjun Ramchandani · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Mouse models of stress disorders and addiction
$2,573,710Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2018 · AA
MACS/WIHS -CCS
$2,569,967Maria Luisa Alcaide · University Of Miami School Of Medicine · U01 · FY2023 · HL
Mood, Brain, and Development Unit
$2,568,613Argyrios Stringaris · National Institute Of Mental Health · ZIA · FY2018 · MH
Clinical Evaluation of PET Radiotracers
$2,566,871Robert Innis · National Institute Of Mental Health · ZIA · FY2023 · MH
Mouse models of stress disorders and addiction
$2,565,800Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2021 · AA
Development of MRI Techniques for Applications in Substance Use Disorders
$2,565,601Yihong Yang · National Institute On Drug Abuse · ZIA · FY2024 · DA